* Amgen Inc., of Thousand Oaks, Calif., was issued U.S.patent 5,441,868, covering the manufacturing process forerythropoietin.

* Biocircuits Corp., of Sunnyvale, Calif., received twoU.S. patents for assays using its lipid-polymertechnology. The first, 5,415,999, relates to immunoassaymethods for incorporating ligands and other receptorsassociated with lipid-polymer biomaterial. The second,5,427,915, relates to assay procedures.

* Editek Inc., of Burlington, N.C., was issued U.S. patent5,435,970, titled "device and method for analysis ofconstituents in biological fluids," covering technology forrapid, self-performing assays for whole blood, such asfingerstick tests.

* Editek Inc., of Burlington, N.C., was issued U.S. patent5,435,970, titled "device and method for analysis ofconstituents in biological fluids," covering technology forrapid, self-performing assays for whole blood, such asfingerstick tests.

* Vestar Inc., of San Dimas, Calif., a subsidiary ofNeXstar Pharmaceuticals Inc., of Boulder, Colo., wasissued U.S. patent 5,441,745 for methods of targetingtumors with intact liposomes. The patent describes themechanism of action for NeXstar's DaunoXome, aliposomal form of the anticancer agent, daunorubicin.

Immunomedics Inc., of Morris Plains, N.J., received U.S.patent 5,443,953 related to imaging and treatments withimmunoconjugates, such as antibodies and antibodyfragments, that have a unique carbohydrate attached as abinding site.

Mitotix Inc., of Cambridge, Mass., received U.S. patent5,443,962 for a series of cell-based assays for inhibitorsof human, fungal and protozoan cdc25 enzymes, whichregulate cell division. Another patent 5,441,880, issued toCold Spring Harbor Laboratory in New York andlicensed to Mitotix, covers human and recombinantversions of two cdc25 proteins.

(c) 1997 American Health Consultants. All rights reserved.